JP2005511625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511625A5 JP2005511625A5 JP2003544044A JP2003544044A JP2005511625A5 JP 2005511625 A5 JP2005511625 A5 JP 2005511625A5 JP 2003544044 A JP2003544044 A JP 2003544044A JP 2003544044 A JP2003544044 A JP 2003544044A JP 2005511625 A5 JP2005511625 A5 JP 2005511625A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- diseases
- compounds
- formula
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000031295 Animal disease Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000003723 serotonin 1A agonist Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126531 | 2001-11-14 | ||
| PCT/EP2002/011464 WO2003042208A1 (en) | 2001-11-14 | 2002-10-14 | Pyrazole derivatives as psychopharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511625A JP2005511625A (ja) | 2005-04-28 |
| JP2005511625A5 true JP2005511625A5 (https=) | 2006-01-05 |
Family
ID=8179188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003544044A Pending JP2005511625A (ja) | 2001-11-14 | 2002-10-14 | 向精神薬としてのピラゾール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050026927A1 (https=) |
| EP (1) | EP1444229A1 (https=) |
| JP (1) | JP2005511625A (https=) |
| KR (1) | KR20050036882A (https=) |
| CN (1) | CN1585768A (https=) |
| BR (1) | BR0214046A (https=) |
| CA (1) | CA2467081A1 (https=) |
| HU (1) | HUP0402124A2 (https=) |
| MX (1) | MXPA04004443A (https=) |
| PL (1) | PL369674A1 (https=) |
| WO (1) | WO2003042208A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
| GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| WO2006002284A1 (en) * | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| WO2012074853A1 (en) | 2010-11-22 | 2012-06-07 | The Regents Of The University Of California | Organic small molecule semiconducting chromophores for use in organic electronic devices |
| ES2707886T3 (es) | 2012-02-14 | 2019-04-05 | Next Energy Tech Inc | Dispositivos electrónicos que usan compuestos semiconductores orgánicos de molécula pequeña |
| US9865821B2 (en) * | 2012-02-17 | 2018-01-09 | Next Energy Technologies, Inc. | Organic semiconducting compounds for use in organic electronic devices |
| CN104768949A (zh) * | 2012-08-24 | 2015-07-08 | 特温蒂斯公司 | 苯并呋咱抗淀粉样蛋白化合物和方法 |
| CN104854175A (zh) * | 2012-12-18 | 2015-08-19 | 默克专利股份有限公司 | 包含噻二唑基的聚合物、这种聚合物的制备和它在有机电子器件中的用途 |
| JP6663361B2 (ja) * | 2014-02-27 | 2020-03-11 | トレヴェンティス コーポレーション | ベンゾフラザンを含有する抗アミロイド化合物 |
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| WO2024124439A1 (zh) * | 2022-12-14 | 2024-06-20 | 苏州大学 | 一种抗菌抗肿瘤增效剂及其合成方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6517196A (en) * | 1995-07-13 | 1997-02-10 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| DE19602505A1 (de) * | 1996-01-25 | 1997-07-31 | Merck Patent Gmbh | 1-(Pyrazol-4-Indol-3-yl)-Piperidine |
-
2002
- 2002-10-14 PL PL02369674A patent/PL369674A1/xx unknown
- 2002-10-14 CA CA002467081A patent/CA2467081A1/en not_active Abandoned
- 2002-10-14 WO PCT/EP2002/011464 patent/WO2003042208A1/en not_active Ceased
- 2002-10-14 MX MXPA04004443A patent/MXPA04004443A/es unknown
- 2002-10-14 CN CNA02822566XA patent/CN1585768A/zh active Pending
- 2002-10-14 HU HU0402124A patent/HUP0402124A2/hu unknown
- 2002-10-14 BR BR0214046-2A patent/BR0214046A/pt not_active Application Discontinuation
- 2002-10-14 KR KR1020047006057A patent/KR20050036882A/ko not_active Withdrawn
- 2002-10-14 EP EP02785208A patent/EP1444229A1/en not_active Withdrawn
- 2002-10-14 US US10/495,456 patent/US20050026927A1/en not_active Abandoned
- 2002-10-14 JP JP2003544044A patent/JP2005511625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060199805A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| CA2599721A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of depression | |
| JP2003529563A (ja) | ビュープロピオン代謝産物並びにその合成および使用方法 | |
| CN1946403A (zh) | 氟班色林在治疗经前期及其他女性的性功能障碍中的用途 | |
| JP2005511625A5 (https=) | ||
| CN1311681A (zh) | 顽固性抑郁治疗的联合疗法 | |
| WO2016199878A1 (ja) | シグマ受容体結合剤 | |
| JP2011502981A (ja) | 新規な１，３−ジヒドロ−５−イソベンゾフランカルボニトリル誘導体およびそれを含む早漏症治療用医薬組成物 | |
| JP6321274B2 (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| WO2006014024A1 (ja) | 精神神経系疾患治療剤 | |
| JP2015189677A (ja) | ソリフェナシン非晶質体を含有する医薬組成物 | |
| JP2008255064A (ja) | 睡眠障害予防治療剤 | |
| JP4360292B2 (ja) | 疼痛閾値低下抑制剤 | |
| JP2011088919A (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
| JP2005522410A (ja) | 動作障害および錐体外路性動作障害を処置するために投与された薬剤により誘発された悪影響の処置のための置換アミノメチルクロマンの新規な使用 | |
| JP2005507901A5 (https=) | ||
| CN1633304A (zh) | 含有α－葡糖苷酶抑制剂和4－氧代丁酸的药物组合物以及它们治疗糖尿病的用途 | |
| HK1093906B (en) | Use of agomelatine in obtaining medicaments intended for the treatmemt of bipolar disorders | |
| HK1152661A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders | |
| HK1068793B (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl] and its physiologically acceptable salts | |
| HK1068793A1 (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl] and its physiologically acceptable salts | |
| JP2008255058A (ja) | 睡眠障害予防治療剤 | |
| HK1081857A (en) | Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |